ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with 89Zr and IRDye 800CW

摘要: CD105 (endoglin) is an independent marker for poor prognosis in more than 10 solid tumor types. The goal of this study was to develop a CD105-specific agent both positron emission tomography (PET) and near-infrared fluorescence (NIRF) imaging, which has potential clinical applications the diagnosis imaged-guided resection tumors. TRC105, chimeric anti-CD105 monoclonal antibody, conjugated NIRF dye (800CW) p-isothiocyanatobenzyl-desferrioxamine (Df-Bz-NCS) before 89Zr-labeling. Another cetuximab, used as isotype-matched control. FACS analysis revealed no difference binding affinity/specificity between TRC105 Df-TRC105-800CW. Serial PET imaging that 4T1 uptake 89Zr-Df-TRC105-800CW 6.3 ± 1.9, 12.3 1.3, 11.4 1.1 %ID/g at 4, 24, 48 h post-injection (p.i.) respectively (n = 3), higher all organs starting from 24 p.i., provided excellent contrast. Tumor measured by vivo ex had linear correlation with values obtained PET, corroborated biodistribution studies. Blocking experiments, control studies 89Zr-Df-cetuximab-800CW, histology confirmed specificity 89Zr-Df-TRC105-800CW. In conclusion, herein we report dual-modality expression breast cancer model, where observed.